1-[[3-[(3R,5R)-5-(3,5-difluorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one
C19H16F2N6O3 — CID 139486481
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[[3-[(3R,5R)-5-(3,5-difluorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one
1-[[3-[(3R,5R)-5-(3,5-difluorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one (PubChem CID 139486481) has the molecular formula C19H16F2N6O3 and a molecular weight of 414.37 g/mol. Its IUPAC name is 1-[[3-[(3R,5R)-5-(3,5-difluorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one.
Molecular Properties
| Compound Name | 1-[[3-[(3R,5R)-5-(3,5-difluorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one |
|---|---|
| PubChem CID | 139486481 |
| Molecular Formula | C19H16F2N6O3 |
| Molecular Weight | 414.37 g/mol |
| Exact Mass | 414.13 |
| IUPAC Name | 1-[[3-[(3R,5R)-5-(3,5-difluorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one |
| SMILES | Cn1cnc2ncn(Cc3nc([C@@H]4CO[C@@H](c5cc(F)cc(F)c5)C4)no3)c(=O)c21 |
| InChI | InChI=1S/C19H16F2N6O3/c1-26-8-22-18-16(26)19(28)27(9-23-18)6-15-24-17(25-30-15)11-4-14(29-7-11)10-2-12(20)5-13(21)3-10/h2-3,5,8-9,11,14H,4,6-7H2,1H3/t11-,14+/m0/s1 |
| InChIKey | GXQZEMNKUGZVBX-SMDDNHRTSA-N |
| XLogP | 2.08 |
| TPSA | 100.86 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 414.37 |
| LogP ≤ 5 | 2.08 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 139486481 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.